• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
dermatology.Connective tissue diseases.(dr.darseem)
 

dermatology.Connective tissue diseases.(dr.darseem)

on

  • 3,220 views

 

Statistics

Views

Total Views
3,220
Views on SlideShare
3,220
Embed Views
0

Actions

Likes
0
Downloads
65
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    dermatology.Connective tissue diseases.(dr.darseem) dermatology.Connective tissue diseases.(dr.darseem) Presentation Transcript

    • Connective tissue disorders
    • The cardinal feature of these conditions is inflammation in the connective tissue which leads to dermal atrophy or sclerosis, to arthritis, and sometimes to abnormalities in other organs. In addition, antibodies form against normal tissues and cellular components; these disorders are therefore classed as autoimmune. The main connective tissue disorders present as a spectrum ranging from the benign cutaneous variants to severe multisystem diseases.
    • Lupus erythematosus Lupus erythematosus (LE) range from the purely cutaneous type (discoid LE), through patterns associated with some internal problems (disseminated discoid LE and subacute cutaneous LE), to a severe multisystem disease (systemic lupus erythematosus, SLE).
    • Discoid lupus erythematosus: This is the most common form of LE. Patients with discoid LE may have one or two plaques only, or many in several areas. The cause is also unknown but UVR is one factor. Presentation Plaques show erythema, scaling, follicular plugging (like a nutmeg grater), scarring and atrophy, telangiectasia, hypopigmentation and a peripheral zone of hyperpigmentation. They are well demarcated and lie mostly on sun-exposed skin of the scalp, face and ears.
    •  
    • Course -The disease may spread relentlessly, but in about half of the cases the disease goes into remission over the course of several years. -Scarring is common and hair may be lost permanently if there is scarring in the scalp. -Whiteness remains after the inflammation has cleared, and hypopigmentation is common in darkskinned people. -Discoid LE rarely progresses to SLE.
    • Investigations -Most patients with discoid LE remain well. However, screening for SLE and internal disease is still needed. -A skin biopsy is most helpful if taken from an untreated plaque where appendages are still present -Direct immunofluorescence shows deposits of IgG, IgM, IgA and C3 at the basement membrane zone. Biopsies for direct immunofluorescence are best taken from older untreated plaques. -Blood tests are usually normal but occasionally serum contains antinuclear antibodies (in 35%).
    • Differential diagnosis Psoriasis is hard to differentiate from discoid LE when its plaques first arise but has larger thicker scales, and later it is usually symmetrical and affects sites different from those of discoid LE. Discoid LE is more common on the face and ears, and in sun-exposed areas, whereas psoriasis favours the elbows, knees, scalp and sacrum. Discoid LE is far more prone than psoriasis to scar and cause hair loss.
    • Treatment -Discoid LE needs potent or very potent topical corticosteroids. In this condition, it is justifiable to use them on the face, as the risk of scarring is worse than that of atrophy. Topical steroid should be applied twice daily until the lesions disappear or side-effects, such as atrophy, develop; weaker preparations can then be used for maintenance. -If discoid LE does not respond to this, intralesional injections of triamcinolone (2.5 or 10 mg/mL) may help. -Stubborn and widespread lesions often do well with oral antimalarials such as hydroxychloroquine, but rarely these cause irreversible eye damage. The eyes should therefore be tested before and at intervals during treatment. -Sun avoidance and screens are also important. -Oral retinoids and thalidomide have proved helpful in stubborn cases.
    • Subacute cutaneous lupus erythematosus: This is less severe than acute SLE, but is also often associated with systemic disease. Its cause is unknown, but probably involves an antibody-dependent cellular cytotoxic attack on basal cells by K cells bridged by antibody to Ro (SS-A) antigen. Presentation Patients with subacute cutaneous LE are often photosensitive. The skin lesions are sharply marginated scaling psoriasiform plaques, sometimes annular, lying on the forehead, nose, cheeks, chest, hands and extensor surfaces of the arms. They tend to be symmetrical and are hard to tell from discoid LE, or SLE with widespread discoid lesions.
    •  
    • Course As in SLE, the course is prolonged. The skin lesions are slow to clear but, in contrast to discoid LE, do so with little or no scarring. Complications Systemic disease is frequent, but not usually serious. Children born to mothers who have, or have had, this condition are liable to neonatal LE with transient annular skin lesions and permanent heart block. Differential diagnosis The morphology is characteristic, but lesions can be mistaken for psoriasis or widespread discoid LE. Annular lesions may resemble tinea corporis or figurate erythemas.
    • Investigations Patients with subacute cutaneous LE should be evaluated in the same way as those with acute SLE, although deposits of immunoglobulins in the skin and antinuclear antibodies in serum are present less often (80%). Many have antibodies to the cytoplasmic antigen Ro (SS-A) in 60%. Treatment Subacute cutaneous LE does better with antimalarials, such as hydroxychloroquine , than acute SLE. Oral retinoids are also effective in some cases. Systemic steroids may be needed too.
    • Systemic lupus erythematosus (SLE): Cause This is unknown, but -hereditary factors, e.g. complement deficiency and certain HLA types, increase susceptibility. -Particles looking like viruses have been seen in endothelial cells, and in other tissues, but their role is not clear. -Patients with LE have autoantibodies to DNA, nuclear proteins and to other normal antigens, and this points to an autoimmune cause. -Exposure to sunlight and artificial ultraviolet radiation (UVR), pregnancy and infection may precipitate the disease or lead to flare-ups. -Drugs, such as hydralazine and procainamide trigger SLE in a dose-dependent way,others like oral contraceptives, anticonvulsants, minocycline and captopril, precipitate the disease occasionally.
    • Presentation Typically, but not always, the onset is acute. SLE is an uncommon disorder, affecting women more often than men (in a ratio of about 8 : 1). The classic rash of acute SLE is an erythema of the cheeks and nose in the rough shape of a butterfly, with facial swelling. Occasionally, a few blisters may be seen. Some patients develop widespread discoid papulosquamous plaques very like those of discoid LE; others, about 20% of patients, have no skin disease at any stage. Other dermatological features include peri-ungual telangiectasia, erythema over the digits, hair fall (especially at the frontal margin of the scalp), and photosensitivity. Ulcers may occur on the palate, tongue or buccal mucosa.
    • Course The skin changes may be transient, continuous or recurrent; they correlate well with the activity of the systemic disease. Acute SLE may be associated with fever, arthritis, nephritis, polyarteritis, pleurisy, pneumonitis, pericarditis, myocarditis and involvement of the central nervous system. Internal involvement can be fatal, but the overall prognosis now is for about three-quarters of patients to survive for 15 years. Renal involvement suggests a poorer prognosis.
    •  
    •  
    •  
    • Differential diagnosis SLE is a great imitator. -Its malar rash can be confused with sunburn, polymorphic light eruption and rosacea. -The discoid lesions are distinctive, but are also seen in discoid LE and in subacute cutaneous LE. Occasionally, they look like psoriasis or lichen planus. -The hair fall suggests telogen effluvium. -Plaques on the scalp may cause a scarring alopecia. SLE should be suspected when a characteristic rash is combined with fever, malaise and internal disease.
    • Investigations Conduct a full physical examination, looking for internal disease. Biopsy of skin lesions is worthwhile because the pathology and immunopathology are distinctive. There is usually some thinning of the epidermis, liquefaction degeneration of epidermal basal cells, and a mild perivascular mononuclear cell infiltrate. Direct immunofluorescence is helpful: IgG, IgM, IgA and C3 are found individually or together in a band-like pattern at the dermo-epidermal junction of involved skin and often uninvolved skin as well.
    • Antibody screaning: -ANA is positive in upto 100% -Double stranded DNA positive in 50-70% -Ro (SSA) andLa(SSR) may be positive (e.g. 20%) if ANA negative -Cardiolipin is positive in subsets with recurrent abortions, thrombosis and livido reticularis -Histone is positive in drug induced cases
    • Treatment -Systemic steroids are the mainstay of treatment, with bed rest needed during exacerbations. Large doses of prednisolone are often needed to achieve control, as assessed by symptoms, signs, erythrocyte sedimentation rate (ESR), total complement level and tests of organ function. The dosage is then reduced to the smallest that suppresses the disease. -Immunosuppressive agents, such as azathioprine, cyclophosphamide and other drugs (e.g. antihypertensive therapy or anticonvulsants) may also be needed. -Antimalarial drugs may help some patients with marked photosensitivity, as may sunscreens. -Intermittent intravenous infusions of gamma globulin show promise. Long-term and regular follow-up is necessary.
    • Dermatomyositis Dermatomyositis is a subset of polymyositis with distinctive skin changes. There are adult and juvenile types. -The cause is unknown but an autoimmune mechanism seems likely. Autoantibodies to striated muscle are found. -When starting after the age of 40, dermatomyositis may signal an internal malignancy. Presumably, the epitopes of some tumour antigens are so similar to those of muscle antigens that antibodies directed against the tumour cross-react with muscle cells and initiate the disease in a few adults with internal malignancy. -Serological evidence for acute toxoplasmosis in polymyositis-dermatomyositis was found in one series.
    • Presentation The skin signs are characteristic. Typical patients have a faint lilac discoloration around their eyes (sometimes called ‘heliotrope’ because of the colour of the flower). This is associated with malar erythema and oedema and, sometimes, less striking erythema of the neck and presternal area.
    • Most patients also develop lilac slightly atrophic papules over the knuckles of their fingers (Gottron’s papules), streaks of erythema over the extensor tendons of the hand, peri-ungual telangiectasia and ragged cuticles . The skin signs usually appear at the same time as the muscle symptoms but, occasionally, appear months or even years earlier. Sometimes, the skin signs appear in isolation. Many, but not all, patients have weakness of proximal muscles. Climbing stairs, getting up from chairs and combing the hair become difficult.
    •  
    •  
    • Course In children the disorder is often self-limiting, but in adults it may be prolonged and progressive. Raynaud’s phenomenon, arthralgia, dysphagia and calcinosis may follow. The rash may become scaly and, rarely, itchy; eventually that on the light-exposed areas and overlying involved muscles develops poikiloderma. Features of mixed connective disease may develop. The presence of calcinosis suggests a good prognosis.
    • Complications Myositis may lead to permanent weakness and immobility, and inflammation to contractures or cutaneous calcinosis. Some die from progessive and severe myopathy. Differential diagnosis Other connective tissue disorders may look similar, particularly mixed connective tissue disease and SLE. In LE, the finger lesions favour the skin between the knuckles whereas in dermatomyositis the knuckles are preferred. Toxoplasmosis may cause a dermatomyositis-like syndrome. Myopathy can be a side-effect of systemic steroids, so weakness is not always caused by the disease itself.
    • Investigations About 30% of adults with dermatomyositis also have an underlying malignancy. Their dermatomyositis coincides with the onset of the tumour and may improve if it is removed. Adult dermatomyositis or polymyositis therefore requires a search for such an underlying malignancy. The levels of muscle enzymes such as aldolase and creatinine phosphokinase (CPK) are often elevated. Electromyography (EMG) detects muscle abnormalities, and biopsy of an affected muscle shows inflammation and destruction. Surprisingly, the ESR is often normal and antinuclear antibodies may not be detected (positive in 80%). Toxoplasmosis should be excluded by serology.
    • Treatment Systemic steroids, often in high doses (e.g. prednisolone 60 mg/day for an average adult, are the cornerstone of treatment and protect the muscles from destruction. A maintenance regimen may be needed for several years. Immunosuppressive agents, such as azathioprine, also help to control the condition and to reduce the high steroid dose. Cyclosporin and methotrexate have proved useful alternatives in stubborn cases. Maintenance treatment is adjusted according to clinical response and CPK level. As in SLE, intravenous gamma globulin infusions seem promising. Long-term and regular follow-up is necessary.
    • Systemic sclerosis In this disorder the skin becomes hard as connective tissues thicken. Early in the condition, T-helper cells dominate the inflammatory infiltrate in the dermis and cause fibroblasts to proliferate and produce more hyaluronic acid and type I collagen. In addition there is intimal thickening of arterioles and arteries. These processes are not confined to the skin, but involve many other organs, including the gut, lungs, kidneys and heart, leading to their dysfunction and to death.
    • Presentation Most patients suffer from Raynaud’s phenomenon and sclerodactyly. Their fingers become immobile, hard and shiny. Some become hyperpigmented and itchy early in their disease. Peri-ungual telangiectasia is common.
    • Course As the disease progresses, sclerosis spreads to the face, scalp and trunk. The nose becomes beak-like, and wrinkles radiate around the mouth. Most have abnormalities of the gut including dysphagia, oesophagitis, constipation, diarrhoea and malabsorption. Fibrosis of the lungs leads to dyspnoea, and fibrosis of the heart to congestive failure. The kidneys are involved late, but this has a grave prognosis from malignant hypertension.
    •  
    •  
    • Complications Most complications are caused by the involvement of organs other than the skin, but ulcers of the fingertips and calcinosis are distressing. Hard skin immobilizes the joints and leads to contractures
    • Differential diagnosis The differential diagnosis includes chilblains and erythromelalgia. The sclerosis should be distinguished from that of widespread morphoea, porphyria cutanea tarda, mixed connective tissue disease, eosinophilic fasciitis, diabetic sclerodactyly and an acute arthritis with swollen fingers. Rarely the disease is mimicked by progeria, scleromyxoedema, amyloidosis or carcinoid syndrome. Changes like those of progressive systemic sclerosis affect workers exposed to polyvinyl chloride monomers or to severe chronic vibration, and are also seen in chronic graft-vs.-host reactions after bone marrow transplants.
    • Investigations The diagnosis is made clinically because histological abnormalities are seldom present until the physical signs are well established. Laboratory tests should include a fluorescent antinuclear antibody test and the evaluation of the heart, kidney, lungs, joints and muscles. Barium studies are best avoided as obstruction may follow poor evacuation. Other contrast media are available. X-rays of the hands, measurement of muscle enzymes and immunoglobulin levels, and a blood count, ESR and test for the scleroderma associated antibody Scl-70 are also worthwhile.
    • Treatment This is unsatisfactory. The calcium channel blocker nifedipine may help Raynaud’s phenomenon. Systemic steroids, salicylates, antimalarials and longterm penicillin are used, but are not of proven value. d-penicillamine has many side-effects, especially on renal function. Physiotherapy is helpful; photopheresis is experimental. Recently, there have been promising reports of the efficacy of ultraviolet A-1 (340–400 nm) phototherapy for affected skin in systemic sclerosis.
    • CREST syndrome This is a variant of systemic sclerosis with a relatively good prognosis associated often with serum antibodies to nuclear centromeres. The mnemonic stands for C alcinosis, Raynaud’s phenomenon, o E sophageal dysmotility, S clerodactyly and T elangiectasia. Telangiectasia is peri-ungual on the fingers and flat, matlike or rectangular on the face. Many patients with this syndrome develop a diffuse progressive systemic sclerosis after months or years.
    • Eosinophilic fasciitis Localized areas of skin become indurated, sometimes after an upper respiratory tract infection or prolonged severe exercise. Hypergammaglobulinaemia and eosinophilia are present and a deep skin biopsy, which includes muscle, shows that the fascia overlying the muscle is thickened. Despite its name, and despite a profound eosinophilia in the peripheral blood, the fascia is not eosinophilic or permeated by eosinophils. The disease responds promptly to systemic steroids; the long-term prognosis is good but disability in the short term can be severe.
    • Morphoea Morphoea is a localized form of scleroderma with pale indurated plaques on the skin but no internal sclerosis. Many plaques are surrounded by a violaceous halo. Its prognosis is usually good, and the fibrosis slowly clears leaving slight depression and hyperpigmentation. A rare type may lead to arrest of growth of the underlying bones causing, for example, facial hemiatrophy or shortening of a limb. Little is known about the cause, except that Lyme borreliosis may be associated with the disease in Europe but not in the Americas. Treatments work slowly, if at all, and include topical steroids, calcipotriene, non-steroidal anti-inflammatory drugs (NSAIDs), psoralen with ultraviolet A (PUVA), UVA and hydroxychloroquine in selected patients.
    •  
    •  
    • Lichen sclerosus Many think that this condition is related to morphoea, with which it may coexist. However, its patches are non-indurated white shiny macules, sometimes with obvious plugging in the follicular openings. Women are affected far more often than men and, although any area of skin can be involved, the classical ivory coloured lesions often surround the vulva and anus. Intractable itching is common in these areas and the development of vulval carcinoma is a risk. In men the condition may cause stenosis of the urethral meatus, and adhesions between the foreskin and glans of the penis.
    •  
    • Mixed connective tissue disease This is an overlap between SLE and either scleroderma or polymyositis. Presentation As in LE, women are affected more often than men. Many develop swollen hands and sclerodactyly, and skin lesions like those of cutaneous LE may also be present. Alopecia is mild and the hair fall mimics telogen effluvium. Peri-ungual telangiectasia and pigmentary disturbances are common. About 25% of patients have a small vessel vasculitis with palpable purpura, leg ulcers and painful dermal nodules on the hands or elbows. Many show Raynaud’s phenomenon, arthritis, serositis and myositis. Headaches, weakness, fatigue, lymph node enlargement or hoarseness occur in about one in three patients; renal and central nervous system disease are less common.
    • Course The disorder is chronic, and usually turns into either SLE or systemic sclerosis. Differential diagnosis The disorder can be confused with SLE, dermatomyositis, polymyositis, systemic sclerosis and other sclerosing processes such as porphyria cutanea tarda
    • Investigations Patients with mixed connective tissue disease have antibodies in high titre directed against one or more extractable nuclear antigens. These give a speckled pattern when serum is reacted against nuclei and detected by indirect immunofluorescence. Direct immunofluorescence of involved and uninvolved skin shows IgG within the epidermal nuclei, also in a speckled pattern. Only one-third of patients have subepidermal immunoglobulin deposits in involved skin. Most have hypergammaglobulinaemia, a high ESR, oesophageal dysmotility, abnormal pulmonary function tests and a positive rheumatoid factor. Hypocomplementaemia, leucopenia, anaemia, cryoglobulinaemia and falsepositive biological tests for syphilis occur in a few patients.
    • Treatment Treatment depends upon which organs are involved, but systemic steroids are usually needed, in the same dosage as for SLE. Immunosuppressive agents reduce the dosage of systemic steroids, and NSAIDs help with arthralgia, myalgia and swelling of the hands.
    • Other connective tissue diseases Rheumatoid arthritis Most patients with rheumatoid arthritis have no skin disease, but some have tiny fingertip infarcts, purpura, ulcers, palmar or peri-ungual erythema, or pyoderma gangrenosum. The most common skin manifestations are marble-like nodules near joints. These are always associated with the presence of rheumatoid factor. Some patients with rheumatoid arthritis have a vasculitis of larger blood vessels with deep ‘punched out’ ulcers on the legs.
    • Relapsing polychondritis This process can affect any cartilage as the disorder is apparently caused by autoimmunity to collagen. The ears are the usual target. The overlying skin becomes red, swollen and tender. The cartilage in joints, the nose and the tracheo-bronchial tree may be involved, so that patients develop floppy ears, a saddle nose, hoarseness, stridor and respiratory insufficiency. Aortic aneurysms are also seen. Treatment is with systemic steroids and NSAIDs. Tracheostomy may be necessary.